Cases Report: Intravenous Ketamine Infusion for Treatment-Resistant Depression

  • Munchukorn Leelatanon Department of Psychiatry, Faculty of Medicine, Chulalongkorn University
  • Teerayuth Rungnirundorn Department of Psychiatry, Faculty of Medicine, Chulalongkorn University
  • Pornpan Chalermkitpanit Department of Anesthesiology, Faculty of Medicine, Chulalongkorn University
  • Paul Thisayakorn Department of Psychiatry, Faculty of Medicine, Chulalongkorn University
Keywords: Ketamine; treatment-resistant depression; major depressive disorder

Abstract

Objective : To report the results of intravenous ketamine infusion in treatment resistant
mood disorders.
Method : We report 2 patients (treatment resistant bipolar disorder, currently major
depressive episode, and major depressive disorder) who received ketamine infusion
treatment. The clinical data, ketamine infusion process, benefits and adverse effects
were described. Previous studies on ketamine mechanism and therapeutic use was
briefly reviewed.
Results : The depressive symptoms of both cases improved. Both patients reached
the criteria for treatment response within 1 week then remitted clinically within 3-4 weeks.
Significant decreasing of suicidal ideation was also reported. No remarkable adverse
effects from ketamine infusion occurred.
Conclusion : Intravenous ketamine infusion therapy for treatment resistant major
depressive episode was beneficial and safe in these 2 cases. Further researches
regarding its efficacy and safety should be conducted to support the efficacy and
safety of this novel treatment method in Thailand.

Downloads

Download data is not yet available.
Published
2020-03-30
How to Cite
Leelatanon, M., Rungnirundorn, T., Chalermkitpanit, P., & Thisayakorn, P. (2020). Cases Report: Intravenous Ketamine Infusion for Treatment-Resistant Depression. Journal of the Psychiatric Association of Thailand, 65(1), 63-74. Retrieved from https://he01.tci-thaijo.org/index.php/JPAT/article/view/240792